Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770445 | 0.87 | PTPN1 (0.42) | PTPN1CXCR2KDM4E | |
| SCHEMBL5769066 | 0.83 | PTPN1 (0.39) | PTPN1CXCR2 | |
| SCHEMBL5770525 | 0.81 | PTPN1 (0.65) | PTPN1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL5837646 | 0.80 | HPGD (0.42) | PTPN1CXCR2KDM4E | |
| SCHEMBL6315895 | 0.77 | RAB7A (0.47) | CXCR2KDM4EPKMPOLB | |
| SCHEMBL5769105 | 0.77 | PTPN1 (0.59) | PTPN1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL5770835 | 0.76 | NT5E (0.41) | OPRM1CXCR2OPRK1KDM4EPKM | |
| SCHEMBL5771521 | 0.76 | PTPN1 (0.61) | PTPN1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL5769077 | 0.75 | PTPN1 (0.59) | PTPN1OPRM1OPRK1OPRD1 | |
| SCHEMBL5769588 | 0.75 | PTPN1 (0.59) | PTPN1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301516-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-6613903-B2 | Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | PTPRO, PTPN1, PTPRS | PTPN1 2/4885OPRM1 3691/4885CXCR2 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.